Mary S Brady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11635336/publications.pdf

Version: 2024-02-01

186265 233421 10,357 49 28 45 citations h-index g-index papers 50 50 50 14888 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	1.5	39
2	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
3	ASO Author Reflections: Role of Sentinel Lymph Node Biopsy in T1b Melanoma. Annals of Surgical Oncology, 2020, 27, 5257-5258.	1.5	2
4	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. Annals of Surgical Oncology, 2020, 27, 5248-5256.	1.5	12
5	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 939-946.	1.5	41
6	Lymph nodes and the melanoma surgeon: re-defining a long-term relationship. Melanoma Management, 2016, 3, 73-82.	0.5	0
7	Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland. Annals of Surgical Oncology, 2016, 23, 9001-9009.	1.5	18
8	Myoepithelial carcinoma of the extremity: Response to isolated limb infusion. Journal of Surgical Oncology, 2015, 112, 510-513.	1.7	1
9	Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527, 329-335.	27.8	3,688
10	Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. Journal of Surgical Oncology, 2014, 109, 405-409.	1.7	23
11	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. Annals of Surgical Oncology, 2014, 21, 4324-4329.	1.5	13
12	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. Annals of Surgical Oncology, 2013, 20, 3106-3111.	1.5	47
13	Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. Melanoma Research, 2013, 23, 40-46.	1.2	10
14	Advances in sentinel lymph node mapping for patients with melanoma. Future Oncology, 2012, 8, 191-203.	2.4	0
15	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 2012, 18, 883-891.	30.7	3,098
16	Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer, 2012, 118, 3311-3320.	4.1	81
17	Five Hundred Patients With Merkel Cell Carcinoma Evaluated at a Single Institution. Annals of Surgery, 2011, 254, 465-475.	4.2	148
18	Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution. Annals of Surgical Oncology, 2011, 18, 2529-2537.	1.5	164

#	Article	IF	Citations
19	Family Communication Patterns After Melanoma Diagnosis. Journal of Family Communication, 2009, 9, 209-232.	1.6	17
20	An Increased Number of Sentinel Lymph Nodes Is Associated with Advanced Breslow Depth and Lymphovascular Invasion in Patients with Primary Melanoma. Annals of Surgical Oncology, 2009, 16, 948-952.	1.5	19
21	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	3.7	95
22	Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Research, 2009, 19, 106-111.	1.2	26
23	Methods of Detection of First Recurrence in Patients with Stage I/II Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2008, 15, 2206-2214.	1.5	61
24	Subungual melanoma: management considerations. American Journal of Surgery, 2008, 195, 244-248.	1.8	101
25	Family Communication After Melanoma Diagnosis. Archives of Dermatology, 2008, 144, 553-4.	1.4	24
26	Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2007, 25, 869-875.	1.6	266
27	Patterns of First-Recurrence and Post-recurrence Survival in Patients with Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2007, 14, 1934-1942.	1.5	47
28	Yield and Predictors of Radiologic Studies for Identifying Distant Metastases in Melanoma Patients with a Positive Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2007, 14, 2133-2140.	1.5	56
29	A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2006, 13, 1123-1129.	1.5	77
30	Utility of Preoperative [(18)]F Fluorodeoxyglucose–Positron Emission Tomography Scanning in High-Risk Melanoma Patients. Annals of Surgical Oncology, 2006, 13, 525-532.	1.5	83
31	Results of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma. Annals of Surgical Oncology, 2006, 13, 302-309.	1.5	127
32	Prognostic Implications of Multiple Lymphatic Basin Drainage in Patients With Truncal Melanoma. Journal of Clinical Oncology, 2005, 23, 518-524.	1.6	41
33	Sentinel Lymph Node Mapping in Patients With Cutaneous Melanoma. Dermatologic Surgery, 2004, 30, 272-278.	0.8	1
34	Current Management of Patients With Merkel Cell Carcinoma. Dermatologic Surgery, 2004, 30, 321-325.	0.8	28
35	Cutaneous Desmoplastic Melanoma. American Journal of Surgical Pathology, 2004, 28, 1518-1525.	3.7	192
36	Current Management of Patients With Merkel Cell Carcinoma. Dermatologic Surgery, 2004, 30, 321-325.	0.8	10

#	Article	IF	CITATIONS
37	Sentinel Lymph Node Mapping in Patients With Cutaneous Melanoma. Dermatologic Surgery, 2004, 30, 272-278.	0.8	O
38	Prediction of Nonsentinel Lymph Node Status in Melanoma. Annals of Surgical Oncology, 2003, 10, 27-31.	1.5	126
39	Sentinel Lymph Node Biopsy in Patients With Diagnostically Controversial Spitzoid Melanocytic Tumors. American Journal of Surgical Pathology, 2002, 26, 47-55.	3.7	168
40	Sentinel Lymph Node Biopsy in the Management of Patients With Primary Cutaneous Melanoma: Review of a Large Single-Institutional Experience With an Emphasis on Recurrence. Annals of Surgery, 2001, 233, 250-258.	4.2	217
41	Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection. Annals of Surgical Oncology, 2001, 8, 328-337.	1.5	56
42	Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection. Annals of Surgical Oncology, 2001, 8, 328-337.	1.5	5
43	Patterns of detection in patients with cutaneous melanoma. Cancer, 2000, 89, 342-347.	4.1	207
44	PET Scanning with 18F 2-Fluoro-2-Deoxy-?-Glucose (FDG) in Patients with Melanoma Benefits and Limitations. Molecular Imaging and Biology, 1999, 2, 93-98.	0.3	25
45	Radiolocalization of the sentinel lymph node in Merkel cell carcinoma: A clinical analysis of seven cases., 1998, 67, 251-254.		55
46	Lymphatic mapping in the management of melanoma in children Pediatric Dermatology, 1998, 15, 421-425.	0.9	6
47	Lymphatic mapping for Merkel cell carcinoma. Journal of the American Academy of Dermatology, 1997, 37, 650-651.	1.2	28
48	Cutaneous melanoma in patients with sarcoma. , 1997, 79, 843-848.		12
49	Post-treatment sarcoma in breast cancer patients. Annals of Surgical Oncology, 1994, 1, 66-72.	1.5	68